Intermittent Intraputamenal Glial Cell Line–Derived Neurotrophic Factor in Parkinson's Disease: Seeking the Path to Neurorestoration

Cothros, Nicholas; Medina, Alex; Bruno, Verónica

doi:10.1002/mdc3.12757

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Putamen was considered significant in searching out to another brain structure for GDNF infusion (Cothros et al, 2019 ). Dopamine neurons in the brain reside in a region called substantia nigra, but they project their fibers (or axons) to many other locations, including putamen, and this is where much of their dopamine is supplied.…”

Section: Glial Cell Line-derived Neurotrophic Factor Trajectory In CLmentioning

confidence: 99%

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

Kambey

Kanwore

Ayanlaja

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is one of the most common neurodegenerative maladies with unforeseen complex pathologies. While this neurodegenerative disorder’s neuropathology is reasonably well known, its etiology remains a mystery, making it challenging to aim therapy. Glial cell-line derived neurotrophic factor (GDNF) remains an auspicious therapeutic molecule for treating PD. Neurotrophic factor derived from glial cell lines is effective in rodents and nonhuman primates, but clinical findings have been equivocal. Laborious exertions have been made over the past few decades to improve and assess GDNF in treating PD (clinical studies). Definitive clinical trials have, however, failed to demonstrate a survival advantage. Consequently, there seemed to be a doubt as to whether GDNF has merit in the potential treatment of PD. The purpose of this cutting edge review is to speculate as to why the clinical trials have failed to meet the primary endpoint. We introduce a hypothesis, “Failure of GDNF in clinical trials succumbed by nuclear receptor-related factor 1 (Nurr1) shortfall.” We demonstrate how Nurr1 binds to GDNF to induce dopaminergic neuron synthesis. Due to its undisputable neuro-protection aptitude, we display Nurr1 (also called Nr4a2) as a promising therapeutic target for PD.

show abstract

Section: Glial Cell Line-derived Neurotrophic Factor Trajectory In CLmentioning

confidence: 99%

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

Kambey

Kanwore

Ayanlaja

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

SC79 promotes efficient entry of GDNF liposomes into brain parenchyma to repair dopamine neurons through reversible regulation of tight junction proteins

Wang

et al. 2022

Nano Res.

View full text Add to dashboard Cite

Surgical methodology and protocols for preventing implanted cerebral catheters from becoming obstructed during and after neurosurgery

Quintero

Zhang

Pang

et al. 2021

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Intermittent Intraputamenal Glial Cell Line–Derived Neurotrophic Factor in Parkinson's Disease: Seeking the Path to Neurorestoration

Cited by 3 publications

References 5 publications

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

SC79 promotes efficient entry of GDNF liposomes into brain parenchyma to repair dopamine neurons through reversible regulation of tight junction proteins

Surgical methodology and protocols for preventing implanted cerebral catheters from becoming obstructed during and after neurosurgery

Contact Info

Product

Resources

About